Taken together, the present study demonstrates that BR103354 acts as a selective and potent FAP inhibitor and improves insulin resistance, glucose tolerance, and hepatic fibrosis in various animal models, possibly via FAP inhibition. The gene discussed is FAP; the disease is Hepatic fibrosis.